In patients with Ph−/BCR-ABL1 + CML, two patients (7.1%) experienced grade 3 hypophosphatemia and one patient each (3.6%) experienced dermal cyst, pruritus, urticaria, and ALT increase of grade 3 severity; three patients experienced cardiovascular events, including four grade 3 events. This evidence concerns the gene GPT and Pruritus.